Patents by Inventor Kathryn A. Lipford

Kathryn A. Lipford has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Purine inhibitors of human phosphatidylinositol 3-kinase delta
    Patent number: 11179389
    Abstract: The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 23, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Meredeth A. McGowan, Jason D. Katz, Hua Zhou, David James Witter, Chaomin Li, Kathryn A. Lipford, Joey L. Methot, Abdelghani A. Achab, Xavier Fradera, Shimin Xu, Jianmin Fu
  • PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA
    Publication number: 20200390760
    Abstract: The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.
    Type: Application
    Filed: December 12, 2018
    Publication date: December 17, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Meredeth A. McGowan, Jason D. Katz, Hua Zhou, David James Witter, Chaomin Li, Kathryn A. Lipford, Joey L. Methot, Abdelghani A. Achab, Xavier Fradera, Shimin Xu, Jianmin Fu
  • ERK inhibitors
    Patent number: 9546168
    Abstract: Disclosed are the ERK inhibitors of formula (1.0) and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0). This invention provides compounds that are ERK inhibitors (i.e., ERK2 inhibitors). This invention also provides a pharmaceutical composition comprising an effective amount of at least one (e.g., 1) compound of formula (1.0) and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: January 17, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kathryn Lipford, Danielle Falcone, David L. Sloman, David J. Witter
  • ERK INHIBITORS
    Publication number: 20160311819
    Abstract: Disclosed are the ERK inhibitors of formula (1.0) and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0). This invention provides compounds that are ERK inhibitors (i.e., ERK2 inhibitors). This invention also provides a pharmaceutical composition comprising an effective amount of at least one (e.g., 1) compound of formula (1.0) and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 12, 2014
    Publication date: October 27, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kathryn Lipford, Danielle Falcone, David L. Sloman, David J. Witter
  • Compounds that are ERK inhibitors
    Patent number: 9233979
    Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: January 12, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kevin J. Wilson, David J. Witter, Phieng Siliphaivanh, Kathryn Lipford, David Sloman, Danielle Falcone, Brendan O'Boyle, Umar Faruk Mansoor, Jongwon Lim, Joey L. Methot, Christopher Boyce, Lei Chen, Matthew H. Daniels, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Ling Tong, Wei Zhou, Joseph Kozlowski, Milana M. Maletic, Bidhan A. Shinkre, Jayanth Thiruvellore Thatai, Raman Kumar Bakshi, Ganesh Babu Karunakaran
  • Compounds that are ERK inhibitors
    Patent number: 9226922
    Abstract: Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0).
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: January 5, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kevin J. Wilson, David J. Witter, Matthew H. Daniels, Angie R. Angeles, Phieng Siliphaivanh, David Sloman, Brendan O'Boyle, Danielle Falcone, Catherine White, Ron Ferguson, Wei Zhou, Kathryn Lipford, Umar Faruk Mansoor, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Judson E. Richard, Shuyi Tang, Christopher Boyce, Joseph Kozlowski, Raman Kumar Bakshi, Ganesh Babu Karunakaran
  • NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
    Publication number: 20150266895
    Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).
    Type: Application
    Filed: September 26, 2013
    Publication date: September 24, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kevin J. Wilson, David J. Witter, Phieng Siliphaivanh, Kathryn Lipford, David Sloman, Danielle Falcone, Brendan O'Boyle, Umar Faruk Mansoor, Jongwon Lim, Joey L. Methot, Christopher Boyce, Lei Chen, Matthew H. Daniels, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Ling Tong, Wei Zhou, Joseph Kozlowski, Milana M. Maletic, Bidhan A. Shinkre, Jayanth Thiruvellore Thatai, Raman Kumar Bakshi, Ganesh Babu Karunakaran
  • NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
    Publication number: 20150258074
    Abstract: Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0).
    Type: Application
    Filed: September 26, 2013
    Publication date: September 17, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Kevin J. Wilson, David J. Witter, Matthew H. Daniels, Angie R. Angeles, Phieng Siliphaivanh, David Sloman, Brendan O'Boyle, Danielle Falcone, Catherine White, Ron Ferguson, Wei Zhou, Kathryn Lipford, Umar Faruk Mansoor, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Judson E. Richard, Shuyi Tang, Christopher Boyce, Joseph Kozlowski, Raman Kumar Bakshi, Ganesh Babu Karunakaran
  • TYROSINE KINASE INHIBITORS
    Publication number: 20130116231
    Abstract: The present invention relates to 1,4-dihydropyridazinone derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: July 7, 2011
    Publication date: May 9, 2013
    Inventors: Kevin Wilson, Michael Altman, Kathryn Lipford, Catherine White, Matthew Daniels
  • TYROSINE KINASE INHIBITORS
    Publication number: 20120264735
    Abstract: The present invention relates to pyridazin-4(1H)-one derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: December 14, 2010
    Publication date: October 18, 2012
    Inventors: Jonathan Young, Barbara Czako, Michael Altman, David Guerin, Michelle Martinez, Alexey Rivkin, Kevin Wilson, Kathryn Lipford, Catherine White, Laura Surdi, Stephanie Chichetti, Matthew H. Daniels, Sean P. Ahearn, Danielle Falcone, Ekundayo Osimboni